Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ZARONTIN SYRUP 250 MG / 5 ML

ETHOSUXIMIDE : 250 MG / 5 ML · DIN 00023485 · SEARCHLIGHT PHARMA INC

Health Canada status: MARKETED

What is ZARONTIN SYRUP?

ZARONTIN SYRUP 250 MG / 5 ML contains ETHOSUXIMIDE : 250 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 00023485, held by SEARCHLIGHT PHARMA INC, supplied as SYRUP for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Oct-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is ZARONTIN SYRUP used for?

Control of absence (petit mal) epilepsy.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN00023485
Brand nameZARONTIN SYRUP
Generic / active ingredientETHOSUXIMIDE : 250 MG / 5 ML
ManufacturerSEARCHLIGHT PHARMA INC
Strength250 MG / 5 ML
Dosage formSYRUP
Route of administrationORAL
SchedulePrescription
ATC codeN03AD01 ETHOSUXIMIDE
AHFS class28:12.20
BiosimilarNo
Health Canada statusMARKETED
Status date11-Oct-2022
Original market date1964-12-31 00:00:00

How is it administered?

Initial: children 3-6 yrs 250 mg daily; older patients 500 mg daily. Increase by 250 mg every 4-7 days. Optimal dose usually 20 mg/kg/day. Administer in divided doses.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store capsules and syrup between 15 and 25°C. Protect capsules from heat. Protect syrup from freezing and light.

How is it supplied?

Capsules: Bottles of 100. Syrup: Bottles of 500 mL.

Contraindications

Hypersensitivity to ethosuximide, any ingredient in the formulation, or other succinimides.

Warnings and precautions

Serious blood dyscrasias (periodic blood counts required). Serious dermatologic reactions (SJS, DRESS). Suicidal ideation/behavior. May impair ability to drive/operate machinery.

What can be used instead?

Other Canadian products sharing ATC code N03AD01 ETHOSUXIMIDE. 4 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
MAR-ETHOSUXIMIDE250 MGCAPSULEMARCAN PHARMACEUTICALS INCMARKETEDDIN 02545772
ODAN-ETHOSUXIMIDE250 MGCAPSULEODAN LABORATORIES LTDMARKETEDDIN 02547171
ZARONTIN250 MGCAPSULESEARCHLIGHT PHARMA INCMARKETEDDIN 00022799

Who else supplies ETHOSUXIMIDE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ETHOSUXIMIDE appears in 16 registered pack listings across 7 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for ZARONTIN SYRUP

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for ZARONTIN SYRUP

Health Canada Drug Product Database (DPD), DIN 00023485. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.